Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Bio-Vision, Genedata, Ariadne Genomics, Thomas Caskey, Ronald Bowsher, Andrea Ferreira-Gonzalez, Thomas Joos, Gary Procop, James Jacobson

Premium

New Products

Beckman Coulter launched this week its IgY-R7 Rodent Chemistries, which selectively partition seven highly abundant proteins from rat or mouse serum or plasma. The seven proteins captured with the rodent chemistry are albumin, IgG, fibrinogen, transferring, alpha-1-antitrypsin, haptoglobin, and IgM. They make up up to 70 percent of the protein mass.

The IgY-R7 rodent kits are available in three formats: a high-capacity LC column that can yield 25 mg of enriched proteome per day; a medium-capacity LC column that can yield 5 mg of enriched proteome per day; and a pair of spin columns that can yield 4 mg of enriched proteome per day.

In addition, Beckman launched its Single-Component Chemistries kits, which specifically capture a choice of seven highly abundant plasma proteins, thus enabling a more targeted approach for specific protein partitioning. The single-component kits are available for human serum albumin, rat serum albumin, bovine serum albumin, IgG, transferrin, fibrinogen, and HDL. The kits are offered in a spin column format for use with Beckman's ProteomeLab SP Sample Preparation System.


Bio-Vision recently launched its TMiD technology, a MALDI-based tissue imaging platform that enables an operator to image objects placed on a work surface, overlay a user-defined deposition pattern on the image, and print from sub-five nanoliter to hundreds of nanoliters of reagent in a specified pattern. The technology has a point-and-click or drag-and-drop user interface.


Genedata released this week Genedata Expressionist Pro 3.0, a software system that supports proteomics- and metabolomics-based biomarker studies. The new release features a server-based multi-level memory caching system that enables rapid, simultaneous processing of hundreds of MS chromatograms — a prerequisite for the rigorous statistical analysis across several experimental conditions that is common in large-scale proteomics and metabolomics projects, according to the company.


Ariadne Genomics launched this week its PathwayStudio 4.0, a new version of its pathway analysis software formerly known as PathwayAssist. The new software contains new tools for pathway dynamics simulation, microarray data analysis, and over 1,000 reconstructed pathways.

 

Movers & Shakers

Luminex announced the formation of a new scientific advisory board this week. It is comprised of Thomas Caskey, Ronald Bowsher, Andrea Ferreira-Gonzalez, Thomas Joos and Gary Procop. The chairman of the new board is James Jacobson, vice president of R&D at Luminex.

Thomas Caskey is director of the Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center. He has served as president of the American Society of Human Genetics, the Human Genome Organization, and the Academy of Medicine, Engineering and Science of Texas.

Ronald Bowsher is a partner of Bowsher Brunelle Smith and a fellow of the American Association of Pharmaceutical Sciences. He was at Lilly Research Labs until his retirement in 2003.

Ferreira-Gonzalez is a professor of pathology at Virginia Commonwealth University and director of the VCU molecular diagnostics lab. She has served as a member of the clinical laboratory improvement advisory committee at HHS.

Joos is head of the biochemistry department of the NMI Institute at the University of Tubingen. He is a scientific advisor of BioChipNet and a member of the scientific advisory board of the Plasma Proteome Institute in Washington DC.

Procop is head of clinical microbiology at the Cleveland Clinic, which he joined in 1988. Prior to that he was pathology resident at Duke University Medical Center and at Mayo Clinic.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.